Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Mueller

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Blood Advances|September 22, 2023
International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27Simone Oerlemans, Fabio Efficace, Omar Shamieh, et al.
Cancer|May 19, 2023
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20)Simone Oerlemans, Fabio Efficace, Charalampia Kyriakou, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Blood Advances|September 22, 2023
International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27Simone Oerlemans, Fabio Efficace, Omar Shamieh, et al.
Cancer|May 19, 2023
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20)Simone Oerlemans, Fabio Efficace, Charalampia Kyriakou, et al.
Pageof 7